Ascelia Pharma Valuation Multiples

Ascelia Pharma Overview

About Ascelia Pharma

Ascelia Pharma AB is a biotech company focused on orphan oncology treatments. The company develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway. It has two drug candidates, Orviglance and Oncoral, in development. Orviglance (manganese chloride tetrahydrate) is an oral contrast agent for MR imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with impaired kidney function, and Oncoral is a novel oral irinotecan tablet in development.

Founded

1999

HQ

Employees

11

Website

ascelia.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $3M

EBITDA: ($5M)

EV

$40M

Valuation Multiples

Multiples.vc

Start free trial

Ascelia Pharma Financials

Ascelia Pharma reported last 12-month revenue of $3M and negative EBITDA of ($5M).

In the same LTM period, Ascelia Pharma generated $3M in gross profit, ($5M) in EBITDA losses, and had net loss of ($5M).

Ascelia Pharma P&L

In the most recent fiscal year, Ascelia Pharma reported revenue of — and EBITDA of ($8M).

Ascelia Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX

Ascelia Pharma Stock Performance

Ascelia Pharma has current market cap of $45M, and enterprise value of $40M.

Ascelia Pharma's stock price is $0.36.

Ascelia Pharma Valuation Multiples

Ascelia Pharma trades at 14.1x EV/Revenue multiple, and (8.5x) EV/EBITDA.

Ascelia Pharma Financial Valuation Multiples

As of April 18, 2026, Ascelia Pharma has market cap of $45M and EV of $40M.

Equity research analysts estimate Ascelia Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Ascelia Pharma has a P/E ratio of (8.9x).

Ascelia Pharma Margins & Growth Rates

Ascelia Pharma's revenue in the last 12 month grew by 209%.

Ascelia Pharma's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.7M for the same period.

Ascelia Pharma Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Ascelia Pharma M&A Activity

Ascelia Pharma acquired XXX companies to date.

Last acquisition by Ascelia Pharma was on XXXXXXXX, XXXXX. Ascelia Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Ascelia Pharma Investment Activity

Ascelia Pharma invested in XXX companies to date.

Ascelia Pharma made its latest investment on XXXXXXXX, XXXXX. Ascelia Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).